Literature DB >> 28723398

PDL1: The Illusion of an Ideal Biomarker.

Andrea B Apolo1.   

Abstract

Entities:  

Year:  2015        PMID: 28723398      PMCID: PMC6776418          DOI: 10.1016/j.euf.2015.04.005

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


× No keyword cloud information.
  12 in total

1.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

2.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

3.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 9.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

10.  Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma.

Authors:  Andrew S McDaniel; Ajjai Alva; Tianyu Zhan; Hong Xiao; Xuhong Cao; Amy Gursky; Javed Siddiqui; Arul M Chinnaiyan; Hui Jiang; Cheryl T Lee; Rohit Mehra
Journal:  Eur Urol Focus       Date:  2015-06-06
View more
  5 in total

Review 1.  Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Authors:  Thomas Powles; Andrea Necchi; Galit Rosen; Subramanian Hariharan; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

Review 2.  Landscape of Immunotherapy in Genitourinary Malignancies.

Authors:  Deepak Ravindranathan; Omar Alhalabi; Hind Rafei; Amishi Yogesh Shah; Mehmet Asim Bilen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.

Authors:  Heather J Chalfin; Tiziano Pramparo; Amir Mortazavi; Scot A Niglio; Joseph D Schonhoft; Adam Jendrisak; Yen-Lin Chu; Robin Richardson; Rachel Krupa; Amanda K L Anderson; Yipeng Wang; Ryan Dittamore; Sumanta K Pal; Primo N Lara; Mark N Stein; David I Quinn; Seth M Steinberg; Lisa M Cordes; Lisa Ley; Marissa Mallek; Olena Sierra Ortiz; Rene Costello; Jacqueline Cadena; Carlos Diaz; James L Gulley; William L Dahut; Howard Streicher; John J Wright; Jane B Trepel; Donald P Bottaro; Andrea B Apolo
Journal:  Clin Cancer Res       Date:  2020-12-01       Impact factor: 13.801

4.  Comprehensive tumor molecular profile analysis in clinical practice.

Authors:  Mustafa Özdoğan; Eirini Papadopoulou; Nikolaos Tsoulos; Aikaterini Tsantikidi; Vasiliki-Metaxa Mariatou; Georgios Tsaousis; Evgenia Kapeni; Evgenia Bourkoula; Dimitrios Fotiou; Georgios Kapetsis; Ioannis Boukovinas; Nikolaos Touroutoglou; Athanasios Fassas; Achilleas Adamidis; Paraskevas Kosmidis; Dimitrios Trafalis; Eleni Galani; George Lypas; Bülent Orhan; Sualp Tansan; Tahsin Özatlı; Onder Kırca; Okan Çakır; George Nasioulas
Journal:  BMC Med Genomics       Date:  2021-04-14       Impact factor: 3.063

5.  Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Authors:  Seth P Lerner; Dean F Bajorin; Colin P Dinney; Jason A Efstathiou; Susan Groshen; Noah M Hahn; Donna Hansel; David Kwiatkowski; Michael O'Donnell; Jonathan Rosenberg; Robert Svatek; Jeffrey S Abrams; Hikmat Al-Ahmadie; Andrea B Apolo; Joaquim Bellmunt; Margaret Callahan; Eugene K Cha; Charles Drake; Jonathan Jarow; Ashish Kamat; William Kim; Margaret Knowles; Bhupinder Mann; Luigi Marchionni; David McConkey; Lisa McShane; Nilsa Ramirez; Andrew Sharabi; Arlene H Sharpe; David Solit; Catherine M Tangen; Abdul Tawab Amiri; Eliezer Van Allen; Pamela J West; J A Witjes; Diane Zipursky Quale
Journal:  Bladder Cancer       Date:  2016-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.